Almazmomi Meaad A, Esmat Ahmed, Naeem Anjum
Pharmaceutical Care Department, Ministry of National Guard - Health Affairs, Jeddah, SAU.
Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU.
Cureus. 2023 Dec 28;15(12):e51228. doi: 10.7759/cureus.51228. eCollection 2023 Dec.
Acute kidney injury (AKI) is caused by a sudden loss of renal function, resulting in the build-up of waste products and a significant increase in mortality and morbidity. It is commonly diagnosed in critically ill patients, with its occurrence estimated at up to 50% in patients hospitalized in the intensive critical unit. Despite ongoing efforts, the death rate associated with AKI has remained high over the past half-century. Thus, it is critical to investigate novel therapy options for preventing the epidemic. Many studies have found that inflammation and Toll-like receptor-4 (TLR-4) activation have a significant role in the pathogenesis of AKI. Noteworthy, challenges in the search for efficient pharmacological therapy for AKI have arisen due to the multifaceted origin and complexity of the clinical history of people with the disease. This article focuses on kidney injury's epidemiology, risk factors, and pathophysiological processes. Specifically, it focuses on the role of TLRs especially type 4 in disease development.
急性肾损伤(AKI)是由肾功能突然丧失引起的,导致废物积聚,死亡率和发病率显著增加。它通常在危重病患者中被诊断出来,在重症监护病房住院的患者中,其发生率估计高达50%。尽管一直在努力,但在过去半个世纪里,与AKI相关的死亡率一直居高不下。因此,研究预防这种流行病的新治疗方案至关重要。许多研究发现,炎症和Toll样受体4(TLR-4)激活在AKI的发病机制中起重要作用。值得注意的是,由于该疾病患者临床病史的多方面起源和复杂性,在寻找有效的AKI药物治疗方面出现了挑战。本文重点关注肾损伤的流行病学、危险因素和病理生理过程。具体而言,它关注Toll样受体尤其是4型在疾病发展中的作用。